Mylan NV (MYL)
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through two segments: Generic and Specialty. The Generic pharmaceutical business is conducted primarily in the U.S. and Canada; Europe; and India, Australia, Japan, New Zealand and Brazil as well as its export activity into emerging markets. The Specialty pharmaceutical business is conducted by Mylan Specialty L.P. The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom.
|Market Price at 20-11-2017||$36.50|
|Price to Earnings Ratio||7.8|
|Market Capitalisation||$19,576.78 (million)|
|Return on Equity (ROE)||22.9%|